AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$KURA

Burrows Francis sold $225K of KURA

Burrows Francis (Chief Scientific Officer) sold 20,726 shares of Kura Oncology, Inc. (KURA) at $10.83 ($0.22M total) on 2026-09-24.

Original reporting
SEC EDGAR · Burrows Francis
Published Sep 25, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KURA
Neutral
high confidence
Mentioned
$KURA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KURANeutralLow
01

Why it matters

The disclosed sale is modest and does not constitute a material event for Kura Oncology.

02

Market read

Minor insider sell; unlikely to affect trading decisions.

03

What to watch

Potential upcoming clinical data releases could outweigh the sale.

Relevance 4/10Novelty 3/10Timing: filing today

Background

Form 4 filing reports insider transactions; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$KURANeutralHigh confidence
Context

Chief Scientific Officer sold 20,726 shares for $224,514.40 on 2026-09-24.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

The sale amount is small relative to float and typical insider activity; no material change expected.

Market effects

Sector

Limited effect on biotech sector; similar insider sales are common.

Regional

No regional impact.

Global

Not globally relevant.

Counterpoint

What could challenge this read

If the insider has private negative information, the stock could face pressure.

Key entities

  • Officer
    Burrows Francis

    Chief Scientific Officer of Kura Oncology.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KURA insider trading history →

Related articles

$KURAMed

Kura Oncology Q3 Earnings Call Highlights

Kura Oncology (KURA) reported Q3 net loss of $70.2M, down 5% YoY. The company presented plans for ziftomenib, including combination studies and frontline trials, with top-line results expected in 2028. Kura also announced plans for darlifarnib studies and a financing agreement with Oberland Capital. Cash reserves stood at $492M, with guidance for 2026-2028 collaboration revenue.

finance.yahoo.com
$KURAMed

Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE

Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE – KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority sh

SEC EDGAR 8-K
$KURAMedAI 8/10

A leukemia drug’s first results with two other medicines will be presented in December.

Kura Oncology (KURA) and Kyowa Kirin (4151) will present data on ziftomenib, their leukemia drug, at the 2026 ASH Annual Meeting. Key presentations include combination results with quizartinib and gilteritinib, longer-term data with venetoclax and azacitidine, and exploratory analysis in additional AML subtypes. The companies aim to establish ziftomenib as a preferred menin inhibitor for combination treatments. An investor webcast is scheduled for December 15, 2026.

stocktitan.net
$KURAMedAI 8/10

Some rats regained normal blood sugar for a month after an experimental diabetes treatment stopped

Caspian Therapeutics and Kura Oncology (KURA) will discuss the development strategy for KO-7246, an oral menin inhibitor for diabetes, in a webcast. Preclinical findings showed improved glucose control and beta cell expansion in animal models. Caspian plans to conduct a Phase 1 clinical trial to assess safety and insulin production. Kura owns half of Caspian and retains research collaboration rights.

stocktitan.net